COMMUNIQUÉS West-GlobeNewswire

First patient treated in Phase 2 A-TANGO trial for acute-on-chronic liver failure
13/07/2026
Randomized phase 2 study evaluating Yaqrit’s toll-like receptor 4 (TLR4) antagonist YAQ005 alone and in combination with G-CSF for acute-on-chronic liver failure (ACLF) Investigational combination G-TAK is designed to [...]
Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
13/07/2026
CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals [...]
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
13/07/2026
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a [...]
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
13/07/2026
Appointments bring global oncology drug development experience and deepen Board’s operational and regulatory expertise SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: [...]
Solésence Brings Patent-Backed Skin Health Innovation to Hair and Scalp
13/07/2026
New White Label Collection, Powered by WHSPR™ and Kleair™, Debuts with Revitalizing Scalp Serum and Scalp Screen Dry Shampoo SPF 45+ Sunscreen Scalp Screen Dry Shampoo SPF 45+ Sunscreen Named a Finalist for the 2026 [...]
Novo Nordisk A/S - share repurchase programme
13/07/2026
Bagsværd, Denmark, 13 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
13/07/2026
Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE [...]
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
13/07/2026
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to [...]
Geron Announces Appointment of Chinmaya Rath as Chief Business Officer
13/07/2026
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial- [...]
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
13/07/2026
Presentation Highlights Business Progress, Product Development Milestones, and Matters for Stockholder Consideration TUCSON, Ariz., July 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard [...]
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
13/07/2026
INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLC Outcomes continue to compare favourably with historical benchmarks [...]
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
13/07/2026
Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platform TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark [...]
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
13/07/2026
Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using [...]
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
13/07/2026
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, [...]
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
13/07/2026
Globally renowned retina specialist and key opinion leader to provide strategic guidance across clinical development, commercialization, and pipeline initiatives WATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- [...]
VitalHub Announces Acquisition of Buddy Healthcare
13/07/2026
TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (“VitalHub” or the “Company”) announced today that it has acquired Buddy Healthcare Ltd Oy (“Buddy Healthcare”), a care coordination [...]
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
13/07/2026
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization REHOVOT, Israel and HOBOKEN, N.J., July 13, [...]
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
13/07/2026
Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025 Seminal Study Successfully Achieved Primary and Secondary Endpoints, [...]
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
13/07/2026
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE [...]

Pages